Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN144,26144,423,60
Msft0,38
Nokia11,69511,72-1,26
IBM1,57
Mercedes-Benz Group AG49,83549,97-0,75
PFE0,00
19.05.2026 0:30:47
Indexy online
AD Index online
select
AD Index online
 

  • 18.05.2026 15:03:41
Wacker Chemie (WCHG.F, Frankfurt)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
100,00 -0,79 -0,80 7 957
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.05.2026
Popis společnosti

Business Summary: Wacker Chemie AG is a Germany-based manufacturer of specialty chemical products. It operates through four segments: Silicones, Polymers, Biosolutions and Polysilicon. The Silicones segments provides silane, silicone fluids, emulsions, elastomers, sealants and resins to pyrogenic silicas; the Polymers segment offers a range of polymeric binders and additives along with customized services; the Biosolutions segment serves the food, pharmaceutical, life science and agrochemical industries and produces fermenter cysteine and bioengineered cyclodextrins, among others, and the Polysilicon segment manufactures high-purity polysilicon for the solar technology and semiconductor-electronics industries.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Wacker Chemie AG revenues decreased 4% to EUR5.49B. Net loss totaled EUR821.1M vs. income of EUR241M. Revenues reflect Polymers segment decrease of 6% to EUR1.37B, Silicones segment decrease of 3% to EUR2.73B, Asia segment decrease of 42% to EUR1.23B, Europe segment decrease of 37% to EUR827.7M. Net loss reflects Equity Earnings -Before Taxes increase from EUR19.1M (income) to EUR334.7M (expense).



  • Poslední aktualizace: 19.05.2026
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Chief Executive OfficerChristopher Boerner5501.04.202428.08.2018
Executive Vice President, Chief Financial Officer, Member of the Leadership TeamDavid Elkins5701.01.2019
President - RayzeBio Organization, Member of the Leadership TeamBenjamin Hickey5101.01.2024
President - Cell Therapy Organization, Member of the Leadership TeamLynelle Hoch5301.01.2023
Executive Vice President, Chief People Officer, Member of the Leadership TeamAmanda Poole5101.01.2024
Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership TeamGreg Meyers5301.01.2022
Executive Vice President, General Counsel and Chief Policy OfficerCari Gallman4606.05.202501.01.2023
Executive Vice President, Corporate Affairs, Member of the Leadership TeamWendy Bartie5401.01.2025
Executive Vice President, Chief Commercialization Officer, Member of the Leadership TeamAdam Lenkowsky5426.04.202326.04.2023
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership TeamCristian Massacesi5701.08.202501.08.2025